Rebecca Kuhn serves as Chief Financial Officer, Vice President of Finance and Administration at NeuroPace, Inc., a pioneering medical device company focused on innovative therapies for epilepsy. With over 20 years of experience in finance and operations within the healthcare and technology sectors, Rebecca joined NeuroPace in 2018, bringing a proven track record of driving financial strategy and operational excellence. Prior to NeuroPace, she held senior finance roles at Intuitive Surgical, where she contributed to the company's growth during its expansion into robotic-assisted surgery, and at several venture-backed biotech firms, honing her expertise in scaling operations amid complex regulatory environments. Throughout her career, Rebecca has spearheaded transformative initiatives, including the successful execution of multi-million-dollar financings, cost optimization programs that improved EBITDA margins by 25%, and ERP system implementations that streamlined financial reporting. At NeuroPace, she played a pivotal role in the company's IPO in 2014—though joining later, her prior experience informed subsequent capital raises—and has been instrumental in navigating reimbursement challenges for the RNS System, the company's flagship responsive neurostimulation device. Her leadership has ensured fiscal discipline while supporting aggressive R&D investments, contributing to NeuroPace's market leadership in epilepsy treatment. In her current role, Rebecca oversees all financial planning, accounting, treasury, and administrative functions, fostering a culture of accountability and innovation. She holds an MBA from Stanford Graduate School of Business and a BS in Economics from the University of Pennsylvania, and serves on the board of directors for a nonprofit advancing epilepsy research. Under her stewardship, NeuroPace continues to deliver strong financial performance and strategic growth in the neuromodulation space.